Lv5
860 积分 2024-09-23 加入
Targeting ATR in patients with cancer
2天前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
3天前
已完结
Et tu, Brutinib? Demise of a kinase target in rheumatoid arthritis?
1个月前
已关闭
Et tu, Brutinib? Demise of a kinase target in rheumatoid arthritis?
1个月前
已关闭
Effects of orelabrutinib, a BTK inhibitor, on antibody‐mediated platelet destruction in primary immune thrombocytopenia
1个月前
已完结
BTK inhibitors: past, present, and future
1个月前
已完结
Bruton’s tyrosine kinase: A promising target for treating systemic lupus erythematosus
1个月前
已完结
Somatic gain-of-function mutation in TLR7 causes early-onset systemic lupus erythematosus
1个月前
已完结
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
1个月前
已完结
Fragment-Based Anti-inflammatory Agent Design and Target Identification: Discovery of AF-45 as an IRAK4 Inhibitor to Treat Ulcerative Colitis and Acute Lung Injury
1个月前
已完结
皖公网安备34019202002308
